| Removab (catumaxomab) / NeoPharm, Trion Pharma |
ChiCTR1900028626: A two-stage, multi-center, open-label, randomized, controlled trial for comparing the efficacy and safety of intra-peritoneal infusion of catumaxomab and treatment of investigator choice in patients with advanced gastric carcinoma with peritoneal metastasis |
|
|
| Recruiting | 3 | 282 | | catumaxomab ;The treatment of investigator choice | Beijing Cancer Hospital; Guangzhou LintonPharm Co., Ltd., Guangzhou LintonPharm Co.,Ltd. | Gastric carcinoma | | | | |
NCT04222114: Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis |
|
|
| Recruiting | 3 | 282 | RoW | Catumaxomab, The treatment of investigator choice | LintonPharm Co.,Ltd. | Stomach Neoplasms | 03/23 | 08/23 | | |
2010-022810-26: MULTICENTER, OPEN-LABEL PHASE II STUDY TO EVALUATE THE EFFICACY OF A 2-CYCLE IMMUNOTHERAPY WITH THE TRI FUNCTIONAL BISPECIFIC ANTIBODY CATUMAXOMAB (ANTI EPCAM X ANTI-CD3) IN ADDITION TO SYSTEMIC CHEMOTHERAPY IN PATIENTS WITH PERITONEAL CARCINOMATOSIS FROM GASTRIC OR COLORECTAL ADENOCARCINOMA |
|
|
| Ongoing | 2 | 40 | Europe | Removab, Removab (Catumaxomab), Removab (Catumaxomab) | University Witten/Herdecke | PERITONEAL CARCINOMATOSIS FROM GASTRIC OR COLORECTAL ADENOCARCINOMA | | | | |
ChiCTR2100044274: A Multicenter, Non-randomized, Uncontrolled, Open-label Phase I/II Study to Observe the Safety and Preliminary Efficacy of Catumaxomab in Patients with Non-Muscle-Invasive Bladder Cancer who Have Failed or are Intolerant to Bacillus Calmette-Guerin (BCG) Vaccine |
|
|
| Recruiting | 1/2 | 161 | | intravesical catumaxomab | Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University; Guangzhou LintonPharm Co., Ltd., Guangzhou LintonPharm Co.,Ltd. | Bladder Cancer | | | | |
NCT04799847: Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG Vaccine |
|
|
| Recruiting | 1/2 | 161 | RoW | Catumaxomab | LintonPharm Co.,Ltd. | Bladder Cancer | 11/24 | 11/24 | | |
| Recruiting | 1 | 30 | Europe | Catumaxomab | Lindis Biotech GmbH | Urinary Bladder Neoplasms | 12/22 | 12/23 | | |
| LP002 / LintonPharm |
| No trials found |
| LP102 / LintonPharm |
| No trials found |
